Advertisement

Efficacy and toxicity following salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after radiotherapy

      Abstract

      INTRODUCTION

      The management of local relapse after prostate cancer radiotherapy is frequently based on androgen deprivation therapy. The aim of the study was to report Gustave Roussy's experience with salvage prostate brachytherapy.

      PATIENTS AND METHODS

      All cases of localized prostate cancer presenting in an irradiated area who received salvage high dose rate (HDR) brachytherapy from 2013 to 2020 were retrospectively reviewed.

      RESULTS

      A total of 64 patients were included. Median follow up was 30.5 months. Median initial EBRT dose was 70 Gy [Q1-Q3: 70 – 74]. Median PSA at brachytherapy was 6.8 ng/mL [Q1-Q3: 4.4 – 8.7] with a median interval between first and salvage irradiation of 10 years [Q1-Q3: 6.9 – 12.6]. The modality of the first irradiation was an exclusive EBRT in 73% of the cases, mostly with a 3D technique (82%). Dose prescription was two fractions of 12 Gy or 13 Gy associated with androgen deprivation therapy for 63% of the patients. About 23% of the patients were castrate-resistant. Disease free survival at 2 years was 58% in the whole population and 66% in hormone sensitive patients. The only factors associated with disease free survival on multivariate analysis was a high-risk disease at initial diagnosis (HR = 3.59, IC95 [1.75; 7.39], p = 0.0005). Grade 3 urinary and rectal toxicities occurred in 1.5% and 1.5% of the patients, respectively.

      CONCLUSION

      HDR salvage brachytherapy seems to be a safe option for patients presenting with an isolated local relapse of prostate cancer.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Brachytherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • D'Amico A.V.
        • Whittington R.
        • Malkowicz S.B.
        • et al.
        Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
        JAMA. 1998; 280: 969-974https://doi.org/10.1001/jama.280.11.969
        • Cosset J.M.
        • Flam T.
        • Belin L.
        • et al.
        Long-term results of permanent implant prostate cancer brachytherapy: a single-institution study of 675 patients treated between 1999 and 2003.
        Cancer Radiother. 2016; 20: 261-267https://doi.org/10.1016/j.canrad.2016.02.009
        • Grimm P.
        • Billiet I.
        • Bostwick D.
        • et al.
        Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
        BJU Int. 2012; 109 (Suppl 1Doi:): 22-29https://doi.org/10.1111/j.1464-410X.2011.10827.x
        • N Stone Nelson
        • G Stock Richard
        • Ida White
        • Pam Unger
        Patterns of local failure following prostate brachytherapy.
        J Urol. 2007; 177: 1759-1764https://doi.org/10.1016/j.juro.2007.01.069
        • Evangelista L.
        • Zattoni F.
        • Guttilla A.
        • et al.
        Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis.
        Clin Nucl Med. 2013; 38: 305-314https://doi.org/10.1097/RLU.0b013e3182867f3c
        • Fanti S.
        • Minozzi S.
        • Castellucci P.
        • et al.
        PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.
        Eur J Nucl Med Mol Imaging. 2016; 43: 55-69https://doi.org/10.1007/s00259-015-3202-7
        • Caroli P.
        • Sandler I.
        • Matteucci F.
        • et al.
        68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients.
        Eur J Nucl Med Mol Imaging. 2018; 45: 2035-2044https://doi.org/10.1007/s00259-018-4067-3
        • Perera M.
        • Papa N.
        • Roberts M.
        • et al.
        Gallium-68 Prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis.
        Eur Urol. 2020; 77: 403-417https://doi.org/10.1016/j.eururo.2019.01.049
        • Nanni C.
        • Zanoni L.
        • Pultrone C.
        • et al.
        18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
        Eur J Nucl Med Mol Imaging. 2016; 43: 1601-1610https://doi.org/10.1007/s00259-016-3329-1
        • Scarsbrook A.F.
        • Bottomley D.
        • Teoh E.J.
        • et al.
        Effect of 18F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: results From the FALCON Trial.
        Int J Radiat Oncol Biol Phys. 2020; https://doi.org/10.1016/j.ijrobp.2020.01.050
        • van der Poel H.
        • Grivas N.
        • van Leeuwen P.
        • et al.
        The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer.
        World J Urol. 2019; 37: 1485-1490https://doi.org/10.1007/s00345-019-02677-y
        • Kaljouw E.
        • Pieters B.R.
        • Kovács G.
        • Hoskin P.J.
        A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study.
        Radiother Oncol. 2016; 118: 122-130https://doi.org/10.1016/j.radonc.2015.10.021
        • Duchesne G.M.
        • Woo H.H.
        • Bassett J.K.
        • et al.
        Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomized, multicenter, non-blinded, phase 3 trial.
        Lancet Oncol. 2016; 17: 727-737https://doi.org/10.1016/S1470-2045(16)00107-8
        • Cooperberg M.R.
        • Vickers A.J.
        • Broering J.M.
        • Carroll P.R.
        Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.
        Cancer. 2010; 116: 5226-5234https://doi.org/10.1002/cncr.25456
        • Gotto G.T.
        • Yunis L.H.
        • Vora K.
        • et al.
        Impact of prior prostate radiation on complications after radical prostatectomy.
        J Urol. 2010; 184: 136-142https://doi.org/10.1016/j.juro.2010.03.031
        • Chade D.C.
        • Eastham J.
        • Graefen M.
        • et al.
        Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.
        Eur Urol. 2012; 61: 961-971https://doi.org/10.1016/j.eururo.2012.01.022
        • Stephenson A.J.
        • Scardino P.T.
        • Bianco F.J.
        • et al.
        Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy.
        J Urol. 2004; 172: 2239-2243https://doi.org/10.1097/01.ju.0000140960.63108.39
        • Kirisits C.
        • Schmid M.P.
        • Nesvacil N.
        • Pötter R.
        Medical University of Vienna, Vienna, Austria. In: song WY, Tanderup K, Pieters BR, editors. Series in Medical Physics and Biomedical Engineering.
        Taylor & Francis Group. 2017; (6000 Broken Sound Parkway NW, Suite 300, Boca Raton, FL 33487-2742: CRC PressDoi:): 275-284https://doi.org/10.1201/9781315120966-20
        • Proust-Lima C.
        • Taylor J.M.G.
        • Sécher S.
        • et al.
        Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics.
        Int J Radiat Oncol Biol Phys. 2011; 79: 195-201https://doi.org/10.1016/j.ijrobp.2009.10.008
        • Miralbell R.
        • Roberts S.A.
        • Zubizarreta E.
        • Hendry J.H.
        Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.
        Int J Radiat Oncol Biol Phys. 2012; 82: e17-e24https://doi.org/10.1016/j.ijrobp.2010.10.075
        • Miralbell R.
        • Roberts S.A.
        • Zubizarreta E.
        • Hendry J.H.
        Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.
        Int J Radiat Oncol Biol Phys. 2012; 82: e17-e24https://doi.org/10.1016/j.ijrobp.2010.10.075
        • Dasu A.
        • Toma-Dasu I.
        Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients.
        Acta Oncol. 2012; 51: 963-974https://doi.org/10.3109/0284186X.2012.719635
      1. Limbergen E.V., Joiner M. Radiobiology of LDR, HDR, PDR and VLDR Brachytherapy.:21. 2022

        • Roach M.
        • Hanks G.
        • Thames H.
        • et al.
        Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
        Int J Radiat Oncol Biol Phys. 2006; 65: 965-974https://doi.org/10.1016/j.ijrobp.2006.04.029
      2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)- Prostate Cancer - Version 2. 2021.

      3. Common Terminology Criteria for Adverse Events (CTCAE). 2017:155.

        • Gontero P.
        • Marra G.
        • Alessio P.
        • et al.
        Salvage Radical Prostatectomy for Recurrent Prostate Cancer: morbidity and Functional Outcomes from a Large Multicenter Series of Open versus Robotic Approaches.
        J Urol. 2019; 202: 725-731https://doi.org/10.1097/JU.0000000000000327
        • Philippou Y.
        • Parker R.A.
        • Volanis D.
        • Gnanapragasam V.J.
        Comparative oncologic and toxicity outcomes of salvage radical prostatectomy versus nonsurgical therapies for radiorecurrent prostate cancer: a meta–regression analysis.
        Eur Urol Focus. 2016; 2: 158-171https://doi.org/10.1016/j.euf.2015.09.004
        • Valle L.F.
        • Lehrer E.J.
        • Markovic D.
        • et al.
        A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER).
        Eur. Urol. 2020; (S0302283820308745Doi:)https://doi.org/10.1016/j.eururo.2020.11.010
        • Ingrosso G.
        • Becherini C.
        • Lancia A.
        • et al.
        Nonsurgical salvage local therapies for radiorecurrent prostate cancer: a systematic review and meta-analysis.
        Eur Urol Oncol. 2019; https://doi.org/10.1016/j.euo.2018.12.011
        • Kollmeier M.A.
        • McBride S.
        • Taggar A.
        • et al.
        Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: a comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time.
        Brachytherapy. 2017; 16: 1091-1098https://doi.org/10.1016/j.brachy.2017.07.013
        • Henríquez López I.
        • González-San Segundo C.
        • Vegas J.O.
        • et al.
        Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: a comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
        Radiother Oncol. 2019; 141: 156-163https://doi.org/10.1016/j.radonc.2019.09.006
        • Baty M.
        • Créhange G.
        • Pasquier D.
        • et al.
        Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? When? How?.
        Cancer Radiother. 2019; 23: 541-558https://doi.org/10.1016/j.canrad.2019.07.125
        • Maenhout M.
        • Peters M.
        • van Vulpen M.
        • et al.
        Focal MRI-guided salvage high-dose-rate brachytherapy in patients with radiorecurrent prostate cancer.
        Technol Cancer Res Treat. 2017; 16: 1194-1201https://doi.org/10.1177/1533034617741797
        • Chitmanee P.
        • Tsang Y.
        • Tharmalingam H.
        • et al.
        Single-dose focal salvage high dose rate brachytherapy for locally recurrent prostate cancer.
        Clin Oncol. 2020; 32: 259-265https://doi.org/10.1016/j.clon.2019.10.008
        • Sanmamed N.
        • Glicksman R.M.
        • Helou J.
        • et al.
        Case series illustrating the synergistic use of hydrogel spacer and MR-guidance to increase the radiotherapeutic index for localized prostate cancer.
        Tech Innov Patient Support Radiat Oncol. 2019; 11: 22-25https://doi.org/10.1016/j.tipsro.2019.08.002
        • Lee B.
        • Shinohara K.
        • Weinberg V.
        • et al.
        Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: The University of California–San Francisco experience.
        Int J Radiat Oncol Biol Phys. 2007; 67: 1106-1112https://doi.org/10.1016/j.ijrobp.2006.10.012
        • Łyczek J.
        • Kawczyńska M.M.
        • Garmol D.
        • et al.
        HDR brachytherapy as a solution in recurrences of locally advanced prostate cancer.
        J Contemp Brachytherapy. 2009; 1: 105-108
        • Chen C.P.
        • Weinberg V.
        • Shinohara K.
        • et al.
        Salvage HDR Brachytherapy for Recurrent Prostate Cancer After Previous Definitive Radiation Therapy: 5-Year Outcomes.
        Int J Radiat Oncol. 2013; 86 (Biology, PhysicsDoi:): 324-329https://doi.org/10.1016/j.ijrobp.2013.01.027
        • Wojcieszek P.
        • Szlag M.
        • Głowacki G.
        • et al.
        Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure.
        Radiother and Oncol. 2016; 119: 405-410https://doi.org/10.1016/j.radonc.2016.04.032
        • Kukiełka A.M.
        • Hetnał M.
        • Dąbrowski T.
        • et al.
        Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure.
        Strahlenther Onkol. 2014; 190: 165-170https://doi.org/10.1007/s00066-013-0486-z
        • Lewin R.
        • Amit U.
        • Laufer M.
        • et al.
        Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes.
        Radiat Oncol. 2021; 16: 114https://doi.org/10.1186/s13014-021-01839-w
      4. Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5 mg in Patients With Recurrence of Prostate Cancer - Full Text View - ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT01374087. Accessed March 31, 2020.

        • Munoz F.
        • Fiorica F.
        • Caravatta L.
        • et al.
        Outcomes and toxicities of re-irradiation for prostate cancer: a systematic review on behalf of the Re-Irradiation Working Group of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
        Cancer Treat Rev. 2021; 95102176https://doi.org/10.1016/j.ctrv.2021.102176
        • Corkum M.T.
        • Mendez L.C.
        • Chin J.
        • et al.
        A novel salvage option for local failure in prostate cancer, reirradiation using external beam or stereotactic radiation therapy: systematic review and meta-analysis.
        Adv Radiat Oncol. 2020; 5: 965-977https://doi.org/10.1016/j.adro.2020.04.022
        • Jereczek-Fossa B.A.
        • Rojas D.P.
        • Zerini D.
        • et al.
        Reirradiation for isolated local recurrence of prostate cancer: mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT).
        BJR. 2018; 92 (20180494Doi:)https://doi.org/10.1259/bjr.20180494
        • Fuller D.
        • Wurzer J.
        • Shirazi R.
        • et al.
        Retreatment for local recurrence of prostatic carcinoma after prior therapeutic irradiation: efficacy and toxicity of HDR-Like SBRT.
        Int J Radiat Oncol Biol Phys. 2020; 106: 291-299https://doi.org/10.1016/j.ijrobp.2019.10.014
        • Pasquier D.
        • Martinage G.
        • Janoray G.
        • et al.
        Salvage stereotactic body radiation therapy for local prostate cancer recurrence after radiation therapy: a retrospective multicenter study of the GETUG.
        Int J Radiat Oncol. 2019; 105 (Biology, PhysicsDoi:): 727-734https://doi.org/10.1016/j.ijrobp.2019.07.012
        • Scher N.
        • Bauduceau O.
        • Bollet M.
        • et al.
        Stereotactic prostate focal reirradiation therapy for local recurrence: preliminary results of Hartmann Oncology Radiotherapy Group.
        BJR Open. 2019; 1 (20180027Doi:)https://doi.org/10.1259/bjro.20180027
        • Jereczek-Fossa B.A.
        • Marvaso G.
        • Zaffaroni M.
        • et al.
        Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: an ESTRO ACROP Delphi consensus.
        Cancer Treat. Rev. 2021; 98https://doi.org/10.1016/j.ctrv.2021.102206
        • Cornford P.
        • van den Bergh R.C.N.
        • Briers E.
        • et al.
        EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: treatment of relapsing and metastatic prostate cancer.
        Eur Urol. 2021; 79: 263-282https://doi.org/10.1016/j.eururo.2020.09.046
        • Kaljouw E.
        • Pieters B.R.
        • Kovács G.
        • Hoskin P.J.
        A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study.
        Radiotherapy and Oncology. 2016; 118: 122-130https://doi.org/10.1016/j.radonc.2015.10.021
      5. Salvage HDR for Locally Recurrent Prostate Cancer - Full Text View - ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT04231006. Accessed March 30, 2020.

      6. Partial Prostate Salvage High Dose Rate Brachytherapy - Full Text View - ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT03246802. Accessed March 30, 2020.

      7. Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer - Full Text View - ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT01583920. Accessed March 30, 2020.

      8. Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy - Full Text View - ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT03312972. Accessed March 30, 2020.

        • Jiang P.
        • van der Horst C.
        • Kimmig B.
        • et al.
        Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: toxicity and 5-year outcome.
        Brachytherapy. 2017; 16: 186-192https://doi.org/10.1016/j.brachy.2016.09.008
        • Murgic J.
        • Morton G.
        • Loblaw A.
        • et al.
        Focal salvage high dose-rate brachytherapy for locally recurrent prostate cancer after primary radiation therapy failure: results from a prospective clinical trial.
        Int J Radiat Oncol Biol Phys. 2018; 102: 561-567https://doi.org/10.1016/j.ijrobp.2018.06.039
        • Slevin F.
        • Hodgson S.
        • Rodda S.L.
        • et al.
        Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer.
        Clin Transl Radiat Oncol. 2020; 23: 20-26https://doi.org/10.1016/j.ctro.2020.03.010
        • van Son M.
        • Peters M.
        • Moerland M.
        • et al.
        Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: a toxicity assessment of 150 patients.
        Clin Transl Radiat Oncol. 2021; 27: 1-7https://doi.org/10.1016/j.ctro.2020.12.002
        • Yamada Y.
        • Kollmeier M.A.
        • Pei X.
        • et al.
        A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy.
        Brachytherapy. 2014; 13: 111-116https://doi.org/10.1016/j.brachy.2013.11.005
        • Mbeutcha A.
        • Chauveinc L.
        • Bondiau P.Y.
        • et al.
        Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.
        Radiat Oncol. 2017; 12: 49https://doi.org/10.1186/s13014-017-0789-9
        • Tharp M.
        • Hardacre M.
        • Bennett R.
        • et al.
        Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer.
        Brachytherapy. 2008; 7: 231-236https://doi.org/10.1016/j.brachy.2008.03.003
        • Baumann B.C.
        • Baumann J.C.
        • Christodouleas J.P.
        • Soffen E.
        Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
        Brachytherapy. 2017; 16: 291-298https://doi.org/10.1016/j.brachy.2016.12.011
        • Jo Y.
        • Fujii T.
        • Hara R.
        • et al.
        Salvage high-dose-rate brachytherapy for local prostate cancer recurrence after radiotherapy – preliminary results.
        BJU Int. 2012; 109: 835-839https://doi.org/10.1111/j.1464-410X.2011.10519.x